KATHERINE SCHULZ: Open Payments
NPI 1003472481 · KILLEEN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$262 in 12 payments from 8 companies in 2025. Trend: 2023 $668 · 2024 $332 · 2025 $262
Food & beverage: $262
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 3 | $55 |
| Novo Nordisk Inc | 2 | $45 |
| Lilly USA, LLC | 2 | $32 |
| Indivior Inc. | 1 | $32 |
| Astellas Pharma US Inc | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| ABBVIE INC. | 1 | $26 |
| IBSA Pharma Inc. | 1 | $17 |
Products named: SHINGRIX, Wegovy, MOUNJARO, SUBLOCADE, Veozah, REXULTI, VRAYLAR, Tirosint.
Industry payments across TX — which companies pay providers there.
